Two studies presented today at the 8th International Forum on Mood and Anxiety Disorders (IFMAD) in Vienna demonstrated that once-daily SEROQUEL XRTM (quetiapine fumarate extended release tablets) provided significant symptom relief for elderly patients (>65 years of age) with major depressive disorder (MDD) and generalised anxiety disorder (GAD).
Popularity: 1% [?]
Related posts:
- Escitalopram Significantly Improves Quality Of Life In Major Depressive Disorder And Generalised Anxiety Disorder
- SEROQUEL XL® (quetiapine Fumarate Prolonged Release): New Depression And Anxiety Results Presented At IFMAD In Budapest
- SEROQUEL XL® (quetiapine Fumarate Prolonged Release): New Depression And Anxiety Results Presented At IFMAD In Budapest
- AstraZeneca Presents New Depression And Anxiety Results For SEROQUEL XR
- AstraZeneca Presents New Depression And Anxiety Results For SEROQUEL XR
Comments
No Responses to “New Data Presented For SEROQUEL XRTM In Major Depressive Disorder And Generalised Anxiety Disorder”